Cited by 570Radiopharmaceutical Chemistry and ApplicationsRadioactivity and Radon MeasurementsMedical Imaging Techniques and Applications

The DOI matches its Crossref record; 363 of the 363 references it cites were found in a registry or an index.

MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of α-Particle Emitters for Targeted Radionuclide Therapy

Open access

Sgouros, George, Roeske, John C., McDevitt, Michael R., Palm, Stig, Allen, Barry J., Fisher, Darrell R., Brill, A. Bertrand, Song, Hong, Howell, Roger W., Akabani, Gamal·2010·Journal of Nuclear Medicine

DOI 10.2967/jnumed.108.058651PMC PMC5680544

Open this paper in CoChat — free account Open PDF

Abstract

The potential of alpha-particle emitters to treat cancer has been recognized since the early 1900s. Advances in the targeted delivery of radionuclides and radionuclide conjugation chemistry, and the increased availability of alpha-emitters appropriate for clinical use, have recently led to patient trials of radiopharmaceuticals labeled with alpha-particle emitters. Although alpha-emitters have been studied for many decades, their current use in humans for targeted therapy is an important milestone. The objective of this work is to review those aspects of the field that are pertinent to targeted alpha-particle emitter therapy and to provide guidance and recommendations for human alpha-particle emitter dosimetry.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.2967/jnumed.108.058651

Cites

363 of 363 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

THE STOPPING AND RANGE OF IONS IN SOLIDS
Ziegler, J. F. (1988) · Elsevier eBooks · doi:10.1016/b978-0-12-780621-1.50005-8 · Cited by 9,077
THE STOPPING AND RANGE OF IONS IN SOLIDS
Ziegler, J. F. (1984) · Elsevier eBooks · doi:10.1016/b978-0-12-780620-4.50007-0 · Cited by 5,892
Recommendations of the International Commission on Radiological Protection
(1961) · Postgraduate Medical Journal · doi:10.1136/pgmj.37.425.168-b · Cited by 5,868
The Stopping and Range of Ions in Matter
Ziegler, J. F., & Biersack, J. P. (1985) · Springer eBooks · doi:10.1007/978-1-4615-8103-1_3 · Cited by 4,360
Radiobiology for the Radiologist.
(1974) · Annals of Internal Medicine · doi:10.7326/0003-4819-80-3-438_1 · Cited by 3,498
The Stopping and Ranges of Ions in Matter
(1980) · Elsevier eBooks · doi:10.1016/c2013-0-02882-4 · Cited by 3,012
The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy
Thomlinson, R. H., & Gray, L. H. (1955) · British Journal of Cancer · doi:10.1038/bjc.1955.55 · Cited by 2,228
International Commission on Radiological Protection
(1969) · Radiology · doi:10.1148/93.6.1298 · Cited by 2,148
Basic anatomical and physiological data for use in radiological protection: reference values
Valentin, J. (2002) · Annals of the ICRP · doi:10.1016/s0146-6453(03)00002-2 · Cited by 2,024
Report of the task group on reference man
(1979) · Annals of the ICRP · doi:10.1016/0146-6453(79)90123-4 · Cited by 1,715

Show all 363 references

Research works printed but not linked: 32

2005, J Nucl Med., 46, 199S
1990, Antibody Immunoconjugates Radiopharm., 4, 85
1997, Blood., 90, 2245
2006, Cancer Biother Radiopharm., 21, 395
2006, Cancer Biother Radiopharm., 21, 396
2006, J Nucl Med., 47, 1049
International Commission on Radiological Protection. Relative Biological Effectiveness (RBE), Quality Factor (Q), and Radiation Weighting Factor (wR). Philadelphia, PA: Elsevier; 2004. ICRP publication 92.
1964, Cancer Res., 24, 683
1995, J Nucl Med., 36, 259
1989, Lancet., 2, 650
1997, J Nucl Med., 38, 727
2000, J Nucl Med., 41, 941
2007, Ann ICRP., 37, 1
1994, J Nucl Med., 35, 521
1993, J Nucl Med., 34, 1811
1988, Cancer Res., 48, 7022
1992, J Nucl Med., 33, 2167
1994, J Nucl Med., 35, 303
Fisher DR. The microdosimetry of monoclonal antibodies labeled with alpha emitters. In: Schlafke-Stelson AT, Watson EE, eds. Fourth International Radiopharmaceutical Dosimetry Symposium. Oak Ridge, TN: Oak Ridge Associated Universities; 1986:26–36.
Kellerer AM. Analysis of patterns of energy deposition: a survey of theoretical relations in microdosimetry. In: Ebert HG, ed. Proceedings of the Second Symposium on Microdosimetry. Brussels, Belgium: Commission of European Communities; 1970:107–134.
1997, J Nucl Med., 38, 1923
2004, J Nucl Med., 45, 129
2001, J Nucl Med., 42, 1216
1999, J Nucl Med., 40, 37S
1975, J Nucl Med., 16, 248
1999, J Nucl Med., 40, 1935
2002, J Nucl Med., 43, 97
2003, J Nucl Med., 44, 774
2005, J Nucl Med., 46, 1171
1969, J Nucl Med., 10, 7
1999, J Nucl Med., 40, 1947
Goodhead DT. Talk 23, Alpha Emitters, from Session 6, Effects from Specific Sources of Internal Radiation. Presented at: CERRIE Workshop; July 21–23, 2003; Oxford, U.K.

Sorted by citations

Items 301–400 of 570

2-oxo-3-hydroxy-LSD: an important LSD metabolite?
Verstraete, A., & de Velde, E. J. V. (1999) · PubMed · Cited by 10
212Pb-conjugated anti-rat HER2/neu antibody against a neu-N derived murine mammary carcinoma cell line: cell kill and RBE in vitro
Liatsou, I., Yu, J., Bastiaannet, R., Li, Z., Hobbs, R. F., Torgue, J. J.-C., & Sgouros, G. (2022) · International Journal of Radiation Biology · doi:10.1080/09553002.2022.2033341 · Cited by 10
Self-citation
Optimization Processes of Clinical Chelation-Based Radiopharmaceuticals for Pathway-Directed Targeted Radionuclide Therapy in Oncology
Tomiyoshi, K., Wilson, L. J., Mourtada, F., Sims‐Mourtada, J., Namiki, Y., Kamata, W., Yang, D. J., & Inoue, T. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16111458 · Cited by 9
Advances in Dosimetry and Imaging for 203Pb and 212Pb Radiotheranostics
Ramonaheng, K., Qebetu, M., Banda, K., Goorhoo, P., Legodi, K., Mdanda, S., Sibiya, S. M., Mzizi, Y. V., Ndlovu, H., Kabunda, J., et al. (2025) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2025.09.006 · Cited by 9
Artificial Intelligence for Simplified Patient-centered Dosimetry in Radiopharmaceutical Therapies
López-Montes, A., Yousefirizi, F., Chen, Y., Salimi, Y., Seifert, R., Afshar‐Oromieh, A., Uribe, C., Rominger, A., Zaidi, H., Rahmim, A., et al. (2025) · PET Clinics · doi:10.1016/j.cpet.2025.09.010 · Cited by 9
Biodistribution study of 211Pb progeny released from intravenously applied 223Ra labelled TiO2 nanoparticles in a mouse model
Sakmár, M., Kozempel, J., Kučka, J., Janská, T., Štíbr, M., Vlk, M., & Šefc, L. (2024) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2024.108890 · Cited by 9
Targeted Alpha Therapy for Glioblastoma: Review on In Vitro, In Vivo and Clinical Trials
Sabri, M. E., Moghaddasi, L., Wilson, P., Saran, F. H., & Bezak, E. (2024) · Targeted Oncology · doi:10.1007/s11523-024-01071-y · Cited by 9
Geant4 beam model for boron neutron capture therapy: investigation of neutron dose components
Moghaddasi, L., & Bezak, E. (2018) · Australasian Physical & Engineering Sciences in Medicine · doi:10.1007/s13246-018-0617-z · Cited by 9
Characterization of a custom-made 241Am alpha-source for radiobiological studies
Moreira, H., Liberal, F. D. C. G., McMahon, S. J., & Prise, K. M. (2021) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2021.109931 · Cited by 9
Effects of radiation type and delivery mode on a radioresistant eukaryote Cryptococcus neoformans
Shuryak, I., Bryan, R. A., Broitman, J., Marino, S. A., Morgenstern, A., Apostolidis, C., & Dadachova, E. (2015) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2015.02.006 · Cited by 9
Standards for clinical translation
Decristoforo, C., Hayashi, S. F., Bordeau, C., Haddad, F., Viertl, D., Deville, C., Naidoo, C., Pedersen, K. S., Jensen, M., Köster, U., et al. (2022) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.6599180 · Cited by 9
Framework to calculate 225 Ac, 177 Lu, and 161 Tb radiation dose and biological effect in metastatic castration‐resistant prostate cancer treatment
Ghaseminejad, S., Sarno, D. D., Bauman, G. S., & Lee, T. (2025) · Medical Physics · doi:10.1002/mp.18035 · Cited by 8
Refining the clinical utility of [177Lu]Lu/[225Ac]Ac-PSMA tandem RLT in patients with metastatic castration resistant prostate cancer
Widjaja, L., Hornfeck, J., Siegmund, S. C., Gildehaus, F. J., Schmidt-Hegemann, N.-S., Wenter, V., Sheikh, G. T., Klimek, K., Casuscelli, J., Stief, C. G., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07632-1 · Cited by 8
Radiation Dosimetry in Theranostics: A Review
ZANZONICO, P. B. (2025) · Journal of Nuclear Medicine Technology · doi:10.2967/jnmt.125.270852 · Cited by 8
Clinical Image-Based Dosimetry of Actinium-225 in Targeted Alpha Therapy
Ramonaheng, K., Banda, K., Qebetu, M., Goorhoo, P., Legodi, K., Masogo, T., Seebarruth, Y., Mdanda, S., Sibiya, S. M., Mzizi, Y. V., et al. (2026) · Cancers · doi:10.3390/cancers18020321 · Cited by 8
Personalised Dosimetry in Nuclear Medicine: Bridging Physics, Biology and AI for Next Generation Radiopharmaceutical Therapy
Shanmugiah, J., & Kim, J. S. (2026) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-026-00988-8 · Cited by 8
Biodosimetry, can it find its way to the nuclear medicine clinic?
Bolcaen, J., Combrink, N., Spoormans, K., More, S. S., Vandevoorde, C., Fisher, R., & Kleynhans, J. (2023) · Frontiers in Nuclear Medicine · doi:10.3389/fnume.2023.1209823 · Cited by 8
A fast Monte Carlo cell-by-cell simulation for radiobiological effects in targeted radionuclide therapy using pre-calculated single-particle track standard DNA damage data
Lim, A., Andriotty, M., Yusufaly, T., Agasthya, G. A., Lee, B., & Wang, C. C. (2023) · Frontiers in Nuclear Medicine · doi:10.3389/fnume.2023.1284558 · Cited by 8
Wide-band X-ray and gamma-ray imaging of living mouse to reveal pharmacokinetics of At-211
Masubuchi, M., Omata, A., Koshikawa, N., Kataoka, J., Kato, H., Toyoshima, A., Ooe, K., Katayama, D., Teramoto, T., Matsunaga, K., et al. (2022) · Nuclear Instruments and Methods in Physics Research Section A Accelerators Spectrometers Detectors and Associated Equipment · doi:10.1016/j.nima.2022.167581 · Cited by 8
Absorbed fractions for alpha particles in ellipsoidal volumes
Amato, E., Italiano, A., & Baldari, S. (2013) · Physics in Medicine and Biology · doi:10.1088/0031-9155/58/16/5449 · Cited by 8
Comparison of microdosimetry-based absorbed doses to control tumours and clinically obtained tumour absorbed doses in treatments with 223 Ra
Mínguez, P., Roeske, J. C., Mínguez, R., Iturriaga, A. G., & Rodeño, E. (2018) · Physics in Medicine and Biology · doi:10.1088/1361-6560/aacdcc · Cited by 8
Self-citation
Biodistribution and Multicompartment Pharmacokinetic Analysis of a Targeted α Particle Therapy
Tichacek, C. J., Tafreshi, N. K., Kil, H., Engelman, R. W., Doligalski, M. L., Budzevich, M. M., Gage, K. L., McLaughlin, M. L., Wadas, T. J., Silva, A., et al. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00640 · Cited by 8
IPEM topical report: current molecular radiotherapy service provision and guidance on the implications of setting up a dosimetry service
Craig, A. J., Rojas, B., Wevrett, J., Hamer, E., Fenwick, A., & Gregory, R. (2020) · Physics in Medicine and Biology · doi:10.1088/1361-6560/abc707 · Cited by 8
Perspective on the Use of DNA Repair Inhibitors as a Tool for Imaging and Radionuclide Therapy of Glioblastoma
Everix, L., Nair, S., Driver, C. H. S., Goethals, I., Sathekge, M. M., Ebenhan, T., Vandevoorde, C., & Bolcaen, J. (2022) · Cancers · doi:10.3390/cancers14071821 · Cited by 8
Auger Emitting Radiopharmaceuticals for Cancer Therapy
Falzone, N., Cornelissen, B. T., & Vallis, K. A. (2011) · Biological and medical physics series · doi:10.1007/978-94-007-2564-5_28 · Cited by 8
Impact of cell geometry, cellular uptake region, and tumour morphology on 225Ac and 177Lu dose distributions in prostate cancer
Miller, C., Klyuzhin, I. S., Chaussé, G., Brosch-Lenz, J., Koniar, H., Shi, K., Rahmim, A., & Uribe, C. (2024) · EJNMMI Physics · doi:10.1186/s40658-024-00700-9 · Cited by 7
Evaluation of the pharmacokinetics, dosimetry, and therapeutic efficacy for the α-particle-emitting transarterial radioembolization (αTARE) agent [225Ac]Ac-DOTA-TDA-Lipiodol® against hepatic tumors
Josefsson, A., Cortez, A. G., Rajkumar, H., Latoche, J. D., Jaswal, A. P., Day, K. E., Zarisfi, M., Rigatti, L. H., Huang, Z., & Nedrow, J. R. (2023) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-023-00205-3 · Cited by 7
Basics of Physics and Radiobiology for Radiopharmaceutical Therapies
English, K., Knox, S. J., Graves, S. A., & Kiess, A. P. (2022) · Practical Radiation Oncology · doi:10.1016/j.prro.2022.04.004 · Cited by 7
Dosimetry-Based Consideration on Remission and Relapse after Therapy with 223Ra-Dichloride in Castration-Resistant Prostate Cancer (CRPC) with Bone Metastases. A Case Report
Mangano, A. M., Pacilio, M., Ialongo, P., Semprebene, A., Ventroni, G., & Mango, L. (2018) · Diagnostics · doi:10.3390/diagnostics8010018 · Cited by 7
Evaluation of the physical and biological dosimetry methods in iodine-131-treated patients
Özdal, A., Erselcan, T., Özdemir, Ö., Özgüven, Y., Silov, G., & Erdoğan, Z. (2018) · World Journal of Nuclear Medicine · doi:10.4103/wjnm.wjnm_78_17 · Cited by 7
The Rapid Evolution of Theranostics in Radiation Oncology
Buatti, J. M., & Kiess, A. P. (2020) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2020.07.001 · Cited by 7
EANM recommendations for dosimetry in targeted radionuclide therapy with alpha-emitters
Gabiña, P. M., Gleisner, K. S., Chouin, N., Tran‐Gia, J., Koole, M., Cremonesi, M., Denis-Bacelar, A. M., Cassano, B., Verburg, F. A., Brosch-Lenz, J., et al. (2026) · EANM Innovation · doi:10.1016/j.eanmi.2025.100018 · Cited by 6
Low-dose temozolomide selectively increases glioblastoma’s vascular permeability, tumor microenvironment penetration and the killing potential of systemic actinium-225 α-particle dendrimer-radioconjugates improving treatment efficacy
Nair, R. R., Sarkar, A., Hariharan, P., Gabrielson, K. L., Wu, T., Liu, C., Sharma, A., Liyanage, W., Bhujwalla, Z. M., Penet, M., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07332-w · Cited by 6
In silico assessment of cellular damage from Lu‐177, Ac‐225, and Pb‐212 therapeutic radionuclides
Chatzipapas, K., Papachristou, K., Visvikis, D., Incerti, S., Hazle, J. D., & Kagadis, G. C. (2025) · Medical Physics · doi:10.1002/mp.70089 · Cited by 6
Detection and quantification of 223 Ra uptake in bone metastases of patients with castration-resistant prostate carcinoma, with the aim of determining the absorbed dose in the metastases
Mı́nguez, P., de Iturriaga, A. G., Fernández, I. L., & Rodeño, E. (2018) · Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) · doi:10.1016/j.remnie.2017.10.001 · Cited by 6
Alpha-Emitter Radiopharmaceuticals and External Beam Radiotherapy: A Radiobiological Model for the Combined Treatment
Sarnelli, A., Belli, M. L., Azzali, I., Loi, E., Severi, S., & Strigari, L. (2022) · Cancers · doi:10.3390/cancers14041077 · Cited by 6
Head‐to‐head comparison of three chelates reveals DOTAGA promising for 225Ac labeling of anti‐FZD10 antibody OTSA101
Sudo, H., Tsuji, A. B., Sugyo, A., Harada, Y., Nagayama, S., Katagiri, T., Nakamura, Y., & Higashi, T. (2023) · Cancer Science · doi:10.1111/cas.15978 · Cited by 6
Combined, yet separate: cocktails of carriers (not drugs) for actinium-225 α-particle therapy of solid tumors expressing moderate-to-low levels of targetable markers
Nair, R. R., Prasad, A. G., Bhatavdekar, O., Sarkar, A., Gabrielson, K. L., & Sofou, S. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06710-0 · Cited by 6
Comparison between Targeted Radionuclide Therapy of Bone Metastases Based on β-Emitting and α-Emitting Radionuclides
Sadremomtaz, A., & Masoumi, M. (2019) · Journal of medical imaging and radiation sciences · doi:10.1016/j.jmir.2018.12.005 · Cited by 6
Mathematical Model for Evaluation of Tumor Response in Targeted Radionuclide Therapy with 211At Using Implanted Mouse Tumor
Yonekura, Y., Toki, H., Watabe, T., Kaneda‐Nakashima, K., Shirakami, Y., Ooe, K., Toyoshima, A., Nakajima, H., Tomiyama, N., & Bando, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415966 · Cited by 6
Biophysical modeling of low‐energy ion irradiations with NanOx
Alcocer‐Ávila, M., Levrague, V., Delorme, R., Testa, É., & Beuve, M. (2024) · Medical Physics · doi:10.1002/mp.17407 · Cited by 6
Monte Carlo calculations of the cellular S -values for α-particle-emitting radionuclides incorporated into the nuclei of cancer cells of the MDA-MB231, MCF7 and PC3 lines
Rojas-Calderón, E. L., Ávila, O., & Ferro‐Flores, G. (2018) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2018.01.007 · Cited by 6
Design and testing of a microcontroller that enables alpha particle irradiators to deliver complex dose rate patterns
Nawrocki, T., Tritt, T., Neti, P. V. S. V., Rosen, A., Dondapati, A., & Howell, R. W. (2018) · Physics in Medicine and Biology · doi:10.1088/1361-6560/aaf269 · Cited by 6
Self-citation
IDAC-ALPHA: AN ALPHA DOSIMETRY SOFTWARE FOR NORMAL ORGANS AND TISSUES
Andersson, M., Kluge, A., Meyer, T., Koumarianou, E., & Mattsson, S. (2021) · Radiation Protection Dosimetry · doi:10.1093/rpd/ncab046 · Cited by 6
Graphene Quantum Dots for Molecular Radiotherapy: Radiolabeled Graphene Quantum Dots with Radium (223Ra) Showed Potent Effect Against Bone Cancer
Yang, Y., Cardoso-Lima, R., Piperni, S. G., Alencar, L. M. R., & Santos‐Oliveira, R. (2021) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2021.3150 · Cited by 6
Detección y cuantificación de la captación de 223 Ra en metástasis óseas en pacientes con carcinoma de próstata resistente a la castración con vistas a la determinación de la dosis absorbida en dichas metástasis
Mı́nguez, P., Iturriaga, A. G., Fernández, I. L., & Rodeño, E. (2017) · Revista Española de Medicina Nuclear e Imagen Molecular · doi:10.1016/j.remn.2017.04.009 · Cited by 5
Radiobiology and Radiation Dosimetry in Nuclear Medicine
Salvatori, M., Cremonesi, M., Indovina, L., Chianelli, M., Pacilio, M., Danieli, R., Chiesa, C., & ZANZONICO, P. B. (2022) · Springer eBooks · doi:10.1007/978-3-031-05494-5_6 · Cited by 5
The application of radionuclide therapy for breast cancer
Musket, A., Davern, S. M., Elam, B. M., Musich, P. R., Moorman, J. P., & Jiang, Y. (2024) · Frontiers in Nuclear Medicine · doi:10.3389/fnume.2023.1323514 · Cited by 5
Lead‐212/Bismuth‐212 In Vivo Generator Based on Ultrasmall Silver Telluride Nanoparticles
Wang, R., Wolterbeek, H. T., & Denkova, A. G. (2024) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.4121 · Cited by 5
In vitro and in vivo study of 221Fr and 213Bi progeny release from the 225Ac-labelled TiO2 nanoparticles
Sakmár, M., Kozempel, J., Kučka, J., Janská, T., Štíbr, M., Ondrák, L., Fialová, K. O., Vlk, M., Šefc, L., Bruchertseifer, F., et al. (2024) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2024.108973 · Cited by 5
Gravimetric Drop-on-Demand Inkjet Deposition for Imaging Phantoms with Traceable Activity
Jollota, S., Bergeron, D. E., Verkouteren, R. M., Nour, S., Fitzgerald, R., Kwon, O., Radtke, J. L., Bednarz, B. P., Miller, B. W., & DeWerd, L. A. (2024) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2025.111683 · Cited by 5
Therapeutic evaluation of [212Pb]Pb-AB001 and [177Lu]Lu-PSMA-617 in a mouse model of disseminated prostate cancer
Høyvik, A. J. K., Kvassheim, M., Ma, L., Wiig, E., Hillestad, T., Revheim, M.-E. R., Liukaityte, R., Bruland, Ø. S., & Juzeniene, A. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07330-y · Cited by 5
Detailed Chemistry Studies of 225Actinium Labeled Radiopharmaceuticals
Kılbaş, B., & Eryilmaz, K. (2021) · Current Radiopharmaceuticals · doi:10.2174/1874471014666210528123936 · Cited by 5
Bone Marrow Relative Biological Effectiveness for a 212Pb-labeled Anti-HER2/neu Antibody
Liatsou, I., Josefsson, A., Yu, J., Cortez, A. G., Bastiaannet, R., Velarde, E., Davis, K. U., Brayton, C. F., Wang, H., Torgue, J. J.-C., et al. (2022) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2022.07.1842 · Cited by 5
Self-citation
Behaviour, use and safety aspects of astatine-211 solvated in chloroform after dry distillation recovery
Aneheim, E., Hansson, E., Timperanza, C., Jensen, H. J., & Lindegren, S. (2024) · Scientific Reports · doi:10.1038/s41598-024-60615-4 · Cited by 5
Preliminary Production of 211At at the Texas A&M University Cyclotron Institute
Martin, T. M., Bhakta, V., Al-Harbi, A., Hackemack, M. W., Tăbăcaru, G., Tribble, R. E., Shankar, S., & Akabani, G. (2014) · Health Physics · doi:10.1097/hp.0000000000000042 · Cited by 5
Self-citation
A retrospective study on the potential of 99mTc‐HDP imaging before therapy for individualizing treatments with 223Ra‐Cl2 for metastatic castration resistant prostate cancer
Mínguez, P., Rodeño, E., Fernández, I. L., Esteban, A., Martínez‐Indart, L., & Iturriaga, A. G. (2020) · Medical Physics · doi:10.1002/mp.14683 · Cited by 5
Sodium Fluoride-18 and Radium-223 Dichloride Uptake Colocalize in Osteoblastic Mouse Xenograft Tumors
Phelps, T. E., Roy, J., Green, M. V., Seidel, J., Baidoo, K. E., Adler, S., Edmondson, E. F., Butcher, D. O., Matta, J. L., Ton, A., et al. (2021) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2020.4068 · Cited by 5
Milestones in dosimetry for nuclear medicine therapy
Gear, J. I. (2022) · British Journal of Radiology · doi:10.1259/bjr.20220056 · Cited by 5
Computational Nanomaterials Design: towards the Realization of Nanoparticle use in Radiotherapy Case Study 2: Adsorption states of At on Au (111) Surface
Tanudji, J., Aspera, S. M., Kasai, H., Okada, M., Ogawa, T., & Nakanishi, H. (2022) · Physical Science International Journal · doi:10.9734/psij/2022/v26i7752 · Cited by 5
Radiation protection in therapy with radiopharmaceuticals
Hosono, M. (2018) · International Journal of Radiation Biology · doi:10.1080/09553002.2018.1516910 · Cited by 5
Profound immunomodulatory effects of 225 Ac-NM600 drive enhanced anti-tumor response in prostate cancerPreprint
Ferreira, C. A., Potluri, H. K., Massey, C. F., Grudzinski, J. J., Carston, A. M., Clemons, N. C., Thickens, A. S., Rosenkrans, Z. T., Choi, C., Pinchuk, A., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.26.509374 · Cited by 5
Evaluating the Immune Response After Targeted Radionuclide Therapy: Toward a Correlation Between Absorbed Dose and Response
Perrin, J., Overdevest, N., Tamborino, G., & Nonnekens, J. (2025) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2025.06.3855 · Cited by 4
Evaluation of relative biological effectiveness of 225Ac and its decay daughters with Monte Carlo track structure simulations
Hu, Z., Qu, S., Liu, H., Zhang, Y., Yan, S., Hu, A., Qiu, R., Wu, Z., Zhang, H., & Li, J. (2025) · EJNMMI Physics · doi:10.1186/s40658-025-00765-0 · Cited by 4
Diffusing alpha‐emitters radiation therapy: In vivo measurements of effective diffusion and clearance rates across multiple tumor types
Dumančić, M., Heger, G., Luz, I., Vatarescu, M., Weizman, N., Epstein, L., Cooks, T., & Arazi, L. (2025) · Medical Physics · doi:10.1002/mp.70052 · Cited by 4
Influence of Subcellular Localization on the Cytotoxicity of Targeted α-Therapy
Lee, H., Sarkar, S., Xu, K., Martorano, P., Pham, J. M., Park, P. S. U., King, A. P., Lee, H. S., Mankoff, D. A., Pryma, D. A., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.270175 · Cited by 4
State-of-the-art and future developments in dosimetry for SSTR- and PSMA-targeting radioligand therapies
Resch, S., & Delker, A. (2026) · Zeitschrift für Medizinische Physik · doi:10.1016/j.zemedi.2026.03.011 · Cited by 4
A proposed production method for astatinated (At-211) Trastuzumab for use in a Phase I clinical trial
Aneheim, E., Bäck, T. A., Jensen, H. J., Palm, S., & Lindegren, S. (2024) · PLoS ONE · doi:10.1371/journal.pone.0307543 · Cited by 4
Self-citation
Fractionated alpha and mixed beam radiation promote stronger pro-inflammatory effects compared to acute exposure and trigger phagocytosis
Roshan, M. K., Belikov, S. V., Ix, M., Protti, N., Balducci, C., Dodel, R. C., Ross, J. A., & Lundholm, L. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2024.1440559 · Cited by 4
Dosimetry for Radiopharmaceutical Therapy: Practical Implementation, From the AJR Special Series on Quantitative Imaging
ZANZONICO, P. B. (2025) · American Journal of Roentgenology · doi:10.2214/ajr.24.31873 · Cited by 4
MRI detects tubulointerstitial changes in mouse models of radiation‐induced nephropathy
Stabinska, J., Piccolo, J., Chhabra, A., Liatsou, I., Gabrielson, K. L., Li, Z., Mohanta, Z., Sedaghat, F., Hobbs, R. F., Sgouros, G., et al. (2025) · Magnetic Resonance in Medicine · doi:10.1002/mrm.30443 · Cited by 4
Self-citation
Novel Radiopharmaceuticals for Therapy
Guidoccio, F., Mazzarri, S., Depalo, T., Orsini, F., Erba, P. A., & Mariani, G. (2022) · Springer eBooks · doi:10.1007/978-3-031-05494-5_36 · Cited by 4
Dosimetry at cellular level for the alpha-emitting radionuclides actinium-225, astatine-211 and radium-223 for bone metastasis cells from castration resistant prostate cancer
Silva, C. C. O., Maillard, M. S., da Silva, R. L., & de Sá, L. V. (2024) · Physics in Medicine and Biology · doi:10.1088/1361-6560/ad7b9a · Cited by 4
Response to 223Ra-dichloride in castration-resistant prostate cancer with bone metastasis: A case report
Estorch, M., Maroto, P., Carrió, I., Montes, A., & López-Mora, D. A. (2016) · Oncology Letters · doi:10.3892/ol.2016.4762 · Cited by 4
In silico study on radiobiological efficacy of Ac-225 and Lu-177 for PSMA-guided radiotherapy.
Birindelli, G., Drobnjaković, M., Morath, V., Steiger, K., D’Alessandria, C., Gourni, E., Afshar‐Oromieh, A., Weber, W., Rominger, A., Eiber, M., et al. (2021) · doi:10.48350/162500 · Cited by 4
Estimation of absorbed doses in patients’ organs from the released radionuclide-label during radionuclide therapy with 225Ac
Petrova, A. E., Чипига, Л. А., Водоватов, А. В., Stanzhevsky, A. A., Maystrenko, D. N., Lumpov, A. A., Sinyukhin, A. B., Boykov, I. V., & Rameshvili, T. E. (2022) · Radiacionnaâ gigiena · doi:10.21514/1998-426x-2022-15-1-120-131 · Cited by 4
Selectivity Conversion of Protease Inhibitory Antibodies
Lopez, T., Ramirez, A., Benitez, C., Mustafa, Z., Pham, H., Sanchez, R., & Ge, X. (2018) · Antibody Therapeutics · doi:10.1093/abt/tby008 · Cited by 4
Development of an X-ray imaging camera for targeted radionuclide therapy with astatine-211
Kusano, H., Kusumoto, T., Hasegawa, S., & Kodaira, S. (2024) · Radiation Measurements · doi:10.1016/j.radmeas.2024.107247 · Cited by 3
Targeting Tumor-Infiltrating Immune Cells for Targeted Alpha Therapy in Gliomas: Optimization of [225Ac]Ac-DOTA-αCD11b Dosing through PET Imaging
Jaswal, A. P., Josefsson, A., Cortez, A. G., Bhise, A., Li, B., Sneiderman, C. T., Vincze, S. R., Nisnboym, M., Latoche, J. D., Day, K. E., et al. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0996 · Cited by 3
Oral Toxicities of PSMA-Targeted Therapies: Mitigation Strategies and Translational Opportunities
Emperumal, C. P., Kannan, N., Childs, D. S., & Keenan, B. P. (2025) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2025.102452 · Cited by 3
Effective treatment of human prostate carcinoma xenografts with Single-Dose PSMA-targeted [211At]YF2
Feng, Y., Huynh, T. T., Zheng, Y., Banks, R. L., Pomper, M. G., Vaidyanathan, G., & Zalutsky, M. R. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07578-4 · Cited by 3
First-in-human evaluation of [211At]YF2 in patients with metastatic castration-resistant prostate cancer
Wu, X., Xiang, Y., Zalutsky, M. R., Liu, N., Li, X., Du, Y., Feng, Y., Li, F., & Tian, R. (2026) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07754-6 · Cited by 3
Synthesis, Characterization, and Evaluation of Chelators for Radium-223
Southwell, J. W., Gumiela, M., Cowell, J., Brandt, M., Tekin, V., Sterba, J. H., Rosecker, V., Mindt, T. L., & Gasser, G. (2026) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.5c04877 · Cited by 4
Ultrasmall Au 10–12 Nanoclusters: A Novel Platform for 223 Ra‐Targeted Tumor α‐Therapy
Jiang, Y., Yang, H., Jia, G., Hai, W., Huang, R., Wang, P., Zhang, M., Li, D., Chen, Y., Li, X. Y., et al. (2026) · Exploration · doi:10.1002/exp2.70144 · Cited by 3
Radiopharmaceutical Therapy in Oncology: Perspectives from Transatlantic Experts
Deandreis, D., Jacene, H. A., Therasse, P., André, F., Barlési, F., Haigis, K. M., Fizazi, K. S., & Choueiri, T. K. (2026) · Oncology and Therapy · doi:10.1007/s40487-026-00432-z · Cited by 3
Dosimetry Results from the Phase 1b/3 ACTION-1 Trial of [ 225 Ac]Ac-DOTATATE (RYZ101) in Patients with Somatostatin Receptor–Expressing, Well-Differentiated GEP-NETs
Sgouros, G., Ulaner, G. A., He, B., Ghaly, M., Frey, E. C., Kotiah, S. D., Scott, A., Ferreira, D., Sneeden, E. Y., & Morris, M. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.270573 · Cited by 3
Self-citation
On the Use of 203Pb Imaging to Inform 212Pb Dosimetry for 203/212Pb Image-Guided Alpha-Particle Therapy for Cancer
Graves, S. A., Li, M., Lee, D., & Schultz, M. K. (2024) · Springer eBooks · doi:10.1007/978-3-031-33533-4_28 · Cited by 3
Radiolabeling yield dependency of post-dry distillation decay of astatine-211
Hansson, E., Timperanza, C., Jensen, H. J., Eriksson, B., Lindegren, S., & Aneheim, E. (2025) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2025.108999 · Cited by 3
Determination of age specific 131I S-factor values for thyroid using anthropomorphic phantom in geant4 simulations
Rahman, Z., Ahmad, S., Mirza, S. M., Arshed, W., Mirza, N. M., & Ahmed, W. (2014) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2014.03.004 · Cited by 3
Radiobiology and Radiation Dosimetry in Nuclear Medicine
Salvatori, M., Cremonesi, M., Indovina, L., Chianelli, M., Pacilio, M., Chiesa, C., & ZANZONICO, P. B. (2016) · Springer eBooks · doi:10.1007/978-3-319-26067-9_6-1 · Cited by 3
A Theoretical Model for Predicting and Optimizing In Vitro Screening of Potential Targeted Alpha-Particle Therapy Drugs
Ma, W., Wang, X., Liu, W., Ma, H., Su, Y., Yang, Y., Liu, N., Wang, Y., & Yang, G. (2019) · Radiation Research · doi:10.1667/rr15297.1 · Cited by 3
Encapsulation of 67Cu therapeutic radiometal in luminescent lanthanide phosphate core and core-shell nanoparticles
Rojas, J. V., Umretiya, R. V., Higgins, M. C. M., Ermi, A. G., Sundaresan, G., & Zweit, J. (2022) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2022.110296 · Cited by 3
An Investigation on Production Routes of $${}^{\mathbf{230}}$$U Radioisotope Used in Targeted Alpha Therapy by Different Level Density Models
Özdoğan, H., Şekerci, M., KARACA, M. C., Okutan, M., Demir, B., & Kaplan, A. (2022) · Moscow University Physics Bulletin · doi:10.3103/s0027134922060170 · Cited by 3
Pharmacokinetic Comparison of Selective Prostatic Arterial and Intravenous PSMA PET/CT Radioligand Infusions in Primary Prostatic Adenocarcinoma
Kohlbrenner, R. M., Wu, X. J., Nguyen, H. G., Cooperberg, M. R., Chakravarty, T., Carroll, P. R., & Hope, T. A. (2024) · Radiology · doi:10.1148/radiol.232544 · Cited by 3
Impact of intracellular radionuclide distribution in a Monte Carlo biophysical 3D multi‐cellular model for targeted alpha therapy
Levrague, V., Alcocer‐Ávila, M., Otmani, S., Maigne, L., Testa, É., Beuve, M., & Delorme, R. (2025) · Medical Physics · doi:10.1002/mp.17917 · Cited by 3
Alpha Radionuclide Therapy
Knapp, F. F., & Dash, A. K. (2016) · Springer eBooks · doi:10.1007/978-81-322-2607-9_3 · Cited by 3
Bone-Seeking Targeted Radio-Nuclide Therapy BT-RNT) in Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC): Shifting from Palliation to Improving Survival
Nair, V. J. (2014) · Journal of Nuclear Medicine & Radiation Therapy · doi:10.4172/2155-9619.1000202 · Cited by 3
Therapeutic/Theranostic Use of Radionanomedicine
Oh, S. W., & Lee, D. S. (2018) · Biological and medical physics, biomedical engineering · doi:10.1007/978-3-319-67720-0_23 · Cited by 3
Evaluation of the 223Ra-dichloride biodistribution models for the assessment of the doses from internal exposure
Водоватов, А. В., Чипига, Л. А., Petrova, A. E., & Stanzhevsky, A. A. (2020) · Pharmacy Formulas · doi:10.17816/phf20403 · Cited by 3
Alpha particle microdosimetry calculations using a shallow neural network
Wagstaff, P., Gabiña, P. M., Mínguez, R., & Roeske, J. C. (2022) · Physics in Medicine and Biology · doi:10.1088/1361-6560/ac499c · Cited by 3
Self-citation

Authors: Sgouros, G., Roeske, J. C., McDevitt, M. R., Palm, S., Allen, B. J., Fisher, D. R., Brill, A. B., Song, H., Howell, R. W., & Akabani, G.
Affiliations: Johns Hopkins University (US)
Loyola University Medical Center (US)
Memorial Sloan Kettering Cancer Center (US)
International Atomic Energy Agency (AT)
Pacific Northwest National Laboratory (US)
Vanderbilt University (US)
Rutgers, The State University of New Jersey (US)
Texas A&M University (US)
ORCID: Roeske, John C.
McDevitt, Michael R.
Palm, Stig
Fisher, Darrell R.
Brill, A. Bertrand
Howell, Roger W.
Akabani, Gamal
Venue: Journal of Nuclear Medicine
Publisher: Society of Nuclear Medicine
Published: 2010-01-15
Volume: 51
Issue: 2
Pages: 311-328
ISSN: 0161-5505 (ISSN-L)
2159-662X
DOI: 10.2967/jnumed.108.058651
PMC: PMC5680544
OpenAlex: W2018649196
Cited by: 552
References: 363
Citations by year: 2026: 60 · 2025: 58 · 2024: 50 · 2023: 54 · 2022: 50 · 2021: 50 · 2020: 39 · 2019: 34 · 2018: 44 · 2017: 17 · 2016: 21 · 2015: 10 · 2014: 25 · 2013: 11 · 2012: 16
FWCI: 9.79
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Nuclear Medicine (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institute on Aging (P50AG005136)
National Cancer Institute (R01CA109234, R41CA117599, P30CA008748)
National Institute of Biomedical Imaging and Bioengineering (R01EB001994)
National Center for Research Resources (R43RR015155)
Topics: Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
Physical Sciences › Physics and Astronomy › Radiation › Radioactivity and Radon Measurements
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Keywords: alpha-emitting radionuclides, targeted alpha therapy, radiation biology, dosimetry, radionuclide conjugation, radiopharmaceuticals, cancer therapy
MeSH terms: Alpha Particles, Cell Survival, Clinical Trials as Topic, Dose-Response Relationship, Radiation, Female, Humans, Male, Neoplasms, Neoplasms, Radiation-Induced, Pamphlets, Radiation-Protective Agents, Radiobiology, Radioisotopes, Radiotherapy Dosage, Radiotherapy Planning, Computer-Assisted, Relative Biological Effectiveness, Societies, Medical, Cell Death

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of α-Particle Emitters for Targeted Radionuclide Therapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks